RxDoctor Payments Data

Tiffany Vangundy

Physician Assistant · Mansfield, TXNPI 1740630987

Payments from drug & device makers

$13,608in general payments, 2019–2025

Across 682 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$974
  • LEO Pharma Inc.$925
  • Pfizer$712
  • plus $7K from 27 others

What the payments were for

  • Food & beverage$12,83994%
  • Education$7686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,608 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$121,856
Medicare patients
413
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab16$110,472
OtezlaApremilast18$109,669
Cosentyx (2 Syringes)Secukinumab11$80,191
Calcipotriene11$4,101
Fluorouracil59$3,234
Clobetasol Propionate66$2,885
Metronidazole25$1,765
Ketoconazole84$1,502
Fluocinonide36$1,094
ValacyclovirValacyclovir Hcl28$870
Doxycycline Hyclate25$831
Betamethasone Dipropionate18$744
Ciclopirox19$687
Triamcinolone Acetonide58$520
Hydrocortisone47$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$152$109,66918 claims
NovartisCosentyx (2 Syringes)$514$80,19111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →